CPRX News and Press, Catalyst Pharmaceuticals Inc. From 05/09/23

Concluded Positive FDA Type-C Meeting in Early May 2023 Company On Track to Submit an sNDA Early in the Third Quarter of 2023 CORAL GABLES, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical ...

CORAL GABLES, Fla., May 01, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases today announce...

CORAL GABLES, Fla., April 24, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today...

CORAL GABLES, Fla., April 20, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare disea...

2023-04-19 07:51:25 ET Summary The extent to which FIRDAPSE in the treatment of LEMS can support ongoing growth is a big question mark for Catalyst shareholders. The FYCOMPA acquisition comes with more big question marks. Although enjoying comfortable liquidity, Catalyst will ...

2023-04-18 12:00:51 ET Summary Catalyst Pharmaceuticals, Inc. filed a lawsuit against Teva Pharmaceutical Industries Limited's ANDA. At the heart of the situation is a patent that should never have been granted. While courts have not addressed this, instead focusing on orphan ...

2023-04-17 15:42:50 ET Summary Catalyst Pharmaceuticals, Inc. appears to be set up nicely for earnings and revenue growth with a possible expansion of its valuation ratios. Downside appears to be limited, as Catalyst Pharmaceuticals is currently valued in line with its profitable ...

Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) is the focus of IBN's latest stock spotlight. The company's shares have moved 2.49% on the day to $17.69. Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people w...

2023-04-04 10:23:00 ET While there's no telling precisely when a new bull market is going to roll around, it will because eventually one always does. That means now's the time to identify shares of businesses that are positioned to soar once sentiment improves. Biotech Catalyst Pharma...

2023-03-31 06:00:00 ET Summary Defense is sometimes the best offense. In the spirit of March Madness and market volatility, it’s time to get defensive as the banking crisis and market uncertainty fuel U.S. recession risks. As stocks fluctuate and the Fed suggests tighter cr...